Summary Various immunization assays were used to demonstrate the lack of immunogenicity of three BALB/c tumours of spontaneous origin and of a fourth one resulting from foreign body tumorigenesis. All four tumours inhibited the growth of a second implant of the same tumour into the contralateral flank. In our tumour models "concomitant immunity" (1) was not mediated by macrophage or T-cell dependent immune reactions: both thymectomized BALB/c and nude mice (treated or untreated with silica) gave the same results as intact mice; (2) showed some degree of non-specificity, inhibiting the growth of a different tumour in 3/4 cases; though, the existence of a specific component could not be discarded; (3) was proportional to the volume of the primary tumour at the time of the second challenge; (4) was dependent on actively growing primary tumour, not being obtained with progressively increasing daily inocula of irradiated tumour cells; (5) was detectable in an actively growing secondary tumour: recurrent growth after partial surgical excision was inhibited and (6) involved cytostasis of the secondary tumour: a syngeneic graft of the overlying skin led to tumour growth while histological studies revealed the presence of viable tumour cells. It is postulated that "concomitant immunity" or resistance can be generated without the active participation of the immune system and that tumour-related factors are, in certain cases, responsible for blocking the growth of secondary tumours.
In cancer research there is a phenomenon known as "concomitant immunity" according to which a tumour-bearing host resists a second implant of its own tumour at a different site. It was first described by Ehrlich (1906) and Bashford (1908) devised the term. Since then, apart from a few isolated papers (for reviews see Roffo, 1914; Woglom, 1929; Vaage, 1971) this paradoxical phenomenon remained forgotten for almost 60 years. Even now only few laboratories are dedicated to the study of "concomitant immunity" (for review, see Gorelick, 1983b) in spite of its possible relevance to the mechanism of metastasis control. In this regard, it has been repeatedly observed that the removal of a murine metastasizing tumour is followed by an abrupt increase in metastatic growth (Crile & Deodhar, 1971; Gorelik, 1982) . This would suggest that the primary tumour exerted a controlling action on its metastases which could be considered as a natural "secondary implant". On the whole, "concomitant immunity" has been evaluated during the growth of tumours induced by carcinogenic agents which are strongly immunogenic and in consequence an Animals were age and sex matched' within each experiment.
Tumours
The following 4 tumours were used for "concomitant immunity" studies. PX Fibrosarcoma which was induced by a foreign body (glass cylinder) 6 months after s.c. implantation in a BALB/c female, as described previously (Pasqualini et al., 1973 Cold-treated cells Tumour cells (2 x 106) which had been maintained at -1 5°C for 45min were inoculated s.c. 21 and 7 days before tumour challenge.
LB
Sublethal doses Mice which had survived a first tumour implant were re-inoculated with various doses of cell suspensions of the same tumour.
Tumour implantation and excision S.c. tumour implants were surgically excised when their volume had reached 400-600 mm3; 2-3 weeks later, a second tumour implant was carried out in the contralateral flank in the mice which had not relapsed.
Tumour neutralization test
The anti-tumour activity of lymph node or spleen cells of tumour-bearing mice was investigated with the in vivo Winn test (Winn, 1961) Figure 1 , no "concomitant immunity" was detected in animals bearing the smallest primary tumour but was evident in the other two groups bearing larger primary tumours in which only 3/9 and 3/5, respectively, showed tumour growth at the end of the experiment.
"Concomitant immunity" against CM: Seven BALB/c mice received a primary s.c. implant of 2 x 106 CM cells in the right flank (average latency, 50 days); when tumour size reached 600mm3 (n =4) or 2000 mm3 (n = 3), a second s.c. implant of 1.5 x 106 CM cells was carried out in the contralateral flank. The controls (n = 13) received only the second tumour challenge. As shown in Figure 2 , in the presence of the larger primary tumour, the second implant did not grow at all while in the other group the secondary implant showed significantly retarded growth. The observation period between the inoculum in the left flank and the death of the animals was 25-33 days.
"Concomitant immunity" against Px: A total of 46 BALB/c mice were implanted s.c. with a solid fragment (1 mm3) of Px by trocar, in the right flank (average latency, 30 days) and when tumour size reached 600 mm3 (n= 12), 1400 mm3 (n= 12), 2700mm3 (n=12) or 5400mm3 (n=10), a secondary s.c. implant of Px was carried out in the contralateral flank. The controls (n = 28) received only the second tumour challenge. As can be seen in Figure 3 , the growth of the second implant was significantly inhibited in direct proportion to the size of the primary tumours except in the presence of a very large one, in which case, the second implant reached a volume similar to that of the controls.
It is important to point out that in the four models studied the primary tumour grew and killed the host independently of the fate of the second inoculum.
Nonspecificity of "concomitant immunity"
Animals bearing a primary tumour were challenged with a second implant of a different tumour, to test the specificity of "concomitant immunity".
In a first experiment (LB-P388) sixteen (BALB/c x DBA/2) Fl mice were inoculated, on day 0, with 106 LB cells in the right flank and were The participation of T lymphocytes in the development of "concomitant immunity" was studied in both nude mice and in mice thymectomized within 24h after birth. Results are summarized in Table I Table I , "concomitant immunity" was evident in both groups as compared with controls bearing only the second implant and did not differ from that registered in euthymic mice. It is interesting to note that in nude mice LB cells grew more slowly than in normal mice; therefore the second implant was carried out 1 and 2 days later.
"Concomitant immunity" in silica treated mice Since silica treatment is considered to depress the functions of macrophages (Allison et al., 1966; Gorelick, 1983a) and presumably of NK cells (Djeu et al., 1979; Gorelik, 1983a) where OD3 min and OD15 min represent the optic densities of the blood, 3 and 15 min after the carbon injection (Biozzi et al., 1953; Levy & Wheelock, 1975) . Phagocytic activity of 6 BALB/c mice treated 1 day before with i.v. silica was significantly depressed (K= 0.038 + 0.008) as compared with that of 5 normal mice (0.080+0.005; P<0.01).
Undetectable immunogenicity of the four tumours generating "concomitant immunity"
Immunization assays: LB As can be seen in Table   II Miscellaneous observations concerning the mechanism responsible for "concomitant immunity" Taking into account that the development of "concomitant immunity" was proportional to the tumour volume of the first implant, the possibility was considered that the repeated inoculation of irradiated LB cells in progressively larger daily doses, always at the same s.c. site, might mimic tumour load and thereby generate "concomitant immunity". Therefore, 7 BALB/c mice were inoculated s.c. into the right flank with 9 daily doses imitating the increase in volume of a tumour originated from an inoculum of 106 LB cells; on day 6, the animals were challenged s.c. with 105 viable LB cells in the left flank. No decrease, rather a slight increase in tumour size, was observed compared with control mice bearing only the tumour implant in the left flank; i.e. no "concomitant immunity" had been generated. In order to determine whether "concomitant immunity" could inhibit not only secondary implants but also actively growing tumour cells, 18 BALB/c mice were inoculated s.c. with 106 LB cells in both flanks. On day 6, the incipient LB tumour growing in the left flank of 12 mice was partially excised, leaving behind a mass of 2 x I05 or 104 LB cells, while in the remaining 6 mice, the tumour was excised on day 9, leaving behind a cluster of -2x 103 LB cells. The number of LB cells left behind was calculated indirectly in 12 mice which were similarly operated upon and sacrificed to count the remaining tumour cells. The fate of the LB cells left at the operation site in the presence of the growing tumour in the opposite flank was compared with that of controls operated upon in the same way, but not bearing an LB tumour in the right flank. The results showed that 2 x 105 LB remaining cells grew independently of the presence of the tumour in the contralateral flank, while 104 cells grew but at a slightly lower rate than in the corresponding controls. However, when the number of remaining LB cells was around 2 x 103 and the size of the tumour at the contralateral flank was larger, only 1/6 animals showed tumour growth, while in 5/6 controls the tumour grew; the observation period between the operation and the death of the animals was 8-14 days and it is interesting to note that 2 x 105, 104 or 2 x 103 LB growing cells left behind after excision gave rise to a palpable tumour in only 2, 3 and 4 days respectively. This is a very short tumour latency compared with that required for s.c. inocula of 2x 105, 104 or 2 x 103 LB cells: 7, 14 and 18 days, respectively.
In order to determine whether viable tumour cells were present in the lymph nodes draining a second LB implant, which was not growing because of "concomitant immunity", the following experiment was carried out. Two BALB/c nude mice bearing a growing LB tumour in the right flank and a second LB implant in the left flank, were sacrificed; the left axillary and the left inguinal lymph nodes were excised. These 4 nodes were implanted s.c. by trocar in the left flank of 4 BALB/c mice, 2 of which had received in the right flank a s.c. LB implant of 106 cells, 7 days before. The results indicate that as a first implant, these lymph node cells led to tumour growth, but as a second implant they did not grow, demonstrating that the lymph nodes draining non-growing secondary implants contained viable tumour cells which could be inhibited by "concomitant immunity".
Such a cytostatic mechanism was confirmed by a syngeneic skin graft. Donor skin from 8 BALB/c mice came from the site of a second LB implant which had been carried out 7 or 11 days before and which was not growing. In all of 8 grafted mice a tumour developed at the site of the graft and grew progressively, leading to the death of the animals. This would indicate that "concomitant immunity" was capable of blocking tumour growth by sa reversible cytostatic mechanism. As preliminary results, a further confirmation of the cytostatic state of the tumour cells undergoing "concomitant immunity" was obtained from histological studies. (Figure 5 ).
Discussion
"Concomitant immunity" was demonstrated in association with the four tumours studied; three of these arose spontaneously in our mouse colony and the fourth resulted from the implantation of a foreign body; all of them proved to be nonimmunogenic by several immunological procedures. The intensity of "concomitant immunity" was proportional to the tumour volume of the first implant. However, with foreign body tumorigenesis the phenomenon tended to disappear when the first implant had reached a critical size; such a large volume was never attained with the other three tumours which may explain why a terminal decrease in "concomitant immunity" was not seen, although particular differences among tumours in the generation of this phenomenon cannot be discarded.
Three different theories have been proposed to explain "concomitant immunity". Historically, the theory of atrepsis was the first one put forward by Ehrlich (1906 The second theory was originally proposed by Bashford (1908) (Deckers et al., 1973; Vaage, 1971; North et al., 1982) Hewitt et al. (1976) in 27 mouse tumours and by Middle & Embleton (1981) It is possible that "concomitant immunity" could have two different causes: one immunological, detected only with immunogenic tumours and a second one, non-immunological, common to both immunogenic and non-immunogenic tumours: in the latter case, concomitant resistance would be a better denomination. The fact that North & Kirstein (1977) observed that in T-cell deprived mice, "concomitant immunity" generated by immunogenic tumours substantially decreased but did not disappear would favour such an interpretation.
An analysis of the three theories proposed to explain "concomitant immunity" reveals that the mechanisms implicated in its generation are not yet well understood; the data presented herein indicate that "concomitant immunity" or resistance generated by spontaneous non-immunogenic murine tumours would have the following characteristics: (1) It does not seem to be mediated by macrophage or T-cell dependent immune reaction; (2) It has some degree of non specificity: a significant growth inhibition of the secondary implant was obtained in 3/4 different tumour combinations; however, the fact that "concomitant immunity" observed in LB tumour-bearing mice against a second implant of LB was stronger than that observed against P-388 or CS indicates that a specific component (not necessarily immunological in our tumour models) cannot be discarded; (3) It would operate by a cytostatic mechanism: the second tumour implant remains viable as demonstrated by in vivo transplants and by histological studies. Using longpassaged tumours, Gorelik (1983a) arrived at similar conclusions. However, the questions we are now trying to address are how long do the cytostatic tumour cells of the secondary implant remain in this dormant state and whether they will eventually die; (4) Its induction is dependent on a growing tumour mass: it could not be generated with a serial and progressively higher inoculum of irradiated LB tumour cells mimicking the increasing tumour mass; (5) It affects not only secondary tumour grafts but also actively growing tumour cells: recurrent tumour growth after partial surgical excision could be inhibited by "concomitant immunity".
As a final consideration it must be noted that the detection of "concomitant immunity" presents several methodological difficulties. In effect, the long latency period of relatively small secondary implants may signify that the animals can die of the primary tumour before the secondary one has had a change to appear. On the other hand, a very large secondary implant can overcome "concomitant immunity" precluding its observation. Middle & Embleton (1981) working with 5 spontaneous rat tumours of non-detectable immunogenicity observed that only one of them led to "concomitant immunity"; however, with the other four tumours the second implant was carried out when the first one was either slightly or not palpable at all. When we did experiments in the same conditions "concomitant immunity" was not detected; a larger primary tumour, or else a proportionally smaller second inoculum was needed.
It can be argued that the non-proliferation of the secondary tumour due to "concomitant immunity" is comparable to dormant metastases. On the other hand, animal tumours of spontaneous origin have been considered as the most appropriate model for human cancer (Hewitt, 1978) . Therefore, experiments designed to explain the mechanisms involved in "concomitant immunity" with these tumours may eventually be of benefit for the control of human metastases.
